Sponsored by
This is exciting news - but still very early. It has been reported to be used in 8 patients so far. Five of these had an immune response, and one had tumor regression and remained tumor free for 31 months - which is amazing for a recurrent H3K27M mutant diffuse midline glioma patient. There is a trial going on in Germany that should report more data in a year or two.